Patients with COPD had slightly more major adverse cardiovascular events after initiating single-inhaler triple therapy vs a LABA-ICS inhaler.
Inhaled insulin was noninferior to usual care in glycemic control outcomes after 17 weeks among patients with type 1 diabetes.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback